Literature DB >> 16838077

Seven cases of Pompe disease from Greece.

M Kroos1, P Manta, I Mavridou, F Muntoni, D Halley, R Van der Helm, D Zaifeiriou, A Van der Ploeg, A Reuser, H Michelakakis.   

Abstract

We present seven cases of Pompe disease (McKusick 232300; glycogen storage disease type II; acid maltase deficiency) from Greece. The onset of symptoms varied from early childhood to late adulthood, and the patients had quite variable duration of disease. All but one of them had muscle weakness and all had mildly to highly elevated serum creatine kinase. The diagnosis in all cases was confirmed by the finding of acid alpha-glucosidase (EC 3.2.1.3/20) deficiency in cultured skin fibroblasts. Thirteen mutant alleles were identified and nine different pathogenic mutations were encountered. Four were new: c.2071_2072insAGCCG leads to frameshift and total loss of function; c.1856G > A (p.Ser619Asn) leads to 90-95% loss of function; and the splice-site mutations c.1552-3C > G and c.2331+4A > G reduce the number of correct splicing events by more than 90%. The splice-site mutation c.-32-13T > G (IVS1-13T > G) was encountered four times and seems equally common among Greek and other caucasians. The other mutations: c.925G > A (p.Gly309Arg), c.[307T > G; 271G > A] (p.Cys103Gly; Asp91Asn), c.271del and c.1655T > C (p.Leu552Pro) have been reported earlier. Our study highlights the heterogeneity of Pompe disease in Greece and provides tools for diagnosis and carrier detection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838077     DOI: 10.1007/s10545-006-0280-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  An investigation of the properties and possible clinical significance of the lysosomal alpha-glucosidase GAA*2 allele.

Authors:  D M Swallow; M Kroos; A T Van der Ploeg; B Griffiths; I Islam; C B Marenah; A J Reuser
Journal:  Ann Hum Genet       Date:  1989-05       Impact factor: 1.670

2.  Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally "common" in white populations.

Authors:  R Hirschhorn; M L Huie
Journal:  J Med Genet       Date:  1999-01       Impact factor: 6.318

3.  Acid alpha-glucosidase: a new polymorphism in man demonstrable by 'affinity' electrophoresis.

Authors:  D M Swallow; G Corney; H Harris; R Hirschhorn
Journal:  Ann Hum Genet       Date:  1975-05       Impact factor: 1.670

4.  A diagnostic protocol for adult-onset glycogen storage disease type II.

Authors:  M G Ausems; P Lochman; O P van Diggelen; H K Ploos van Amstel; A J Reuser; J H Wokke
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

5.  Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry.

Authors:  M M Hermans; M A Kroos; J A Smeitink; A T van der Ploeg; W J Kleijer; A J Reuser
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

6.  A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II).

Authors:  N Raben; R C Nichols; F Martiniuk; P H Plotz
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

7.  Qualitative and quantitative analysis of the effect of splicing mutations in propionic acidemia underlying non-severe phenotypes.

Authors:  Sonia Clavero; Belén Pérez; Ana Rincón; Magdalena Ugarte; Lourdes R Desviat
Journal:  Hum Genet       Date:  2004-07-02       Impact factor: 4.132

Review 8.  Glycogenosis type II (acid maltase deficiency).

Authors:  A J Reuser; M A Kroos; M M Hermans; A G Bijvoet; M P Verbeet; O P Van Diggelen; W J Kleijer; A T Van der Ploeg
Journal:  Muscle Nerve Suppl       Date:  1995

9.  L-alanine supplementation in late infantile glycogen storage disease type II.

Authors:  Olaf A Bodamer; Dorothea Haas; Monique M Hermans; Arnold J Reuser; Georg F Hoffmann
Journal:  Pediatr Neurol       Date:  2002-08       Impact factor: 3.372

10.  Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.

Authors:  Monique M P Hermans; Dik van Leenen; Marian A Kroos; Clare E Beesley; Ans T Van Der Ploeg; Hitoshi Sakuraba; Ron Wevers; Wim Kleijer; Helen Michelakakis; Edwin P Kirk; Janice Fletcher; Nils Bosshard; Lina Basel-Vanagaite; Guy Besley; Arnold J J Reuser
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

View more
  7 in total

1.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

2.  Newborn screening for lysosomal storage disorders in hungary.

Authors:  Judit Wittmann; Eszter Karg; Sàndor Turi; Elisa Legnini; Gyula Wittmann; Anne-Katrin Giese; Jan Lukas; Uta Gölnitz; Michael Klingenhäger; Olaf Bodamer; Adolf Mühl; Arndt Rolfs
Journal:  JIMD Rep       Date:  2012-03-21

Review 3.  Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.

Authors:  Gauthier Remiche; Dario Ronchi; Francesca Magri; Costanza Lamperti; Andreina Bordoni; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

4.  Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.

Authors:  Aniko Gal; Zoltán Grosz; Beata Borsos; Ildikó Szatmari; Agnes Sebők; Laszló Jávor; Veronika Harmath; Katalin Szakszon; Livia Dezsi; Eniko Balku; Zita Jobbagy; Agnes Herczegfalvi; Zsuzsanna Almássy; Levente Kerényi; Maria Judit Molnar
Journal:  Life (Basel)       Date:  2021-05-31

5.  Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship.

Authors:  Simone Sampaolo; Teresa Esposito; Olimpia Farina; Daniela Formicola; Daria Diodato; Fernando Gianfrancesco; Federica Cipullo; Gaetana Cremone; Mario Cirillo; Luca Del Viscovo; Antonio Toscano; Corrado Angelini; Giuseppe Di Iorio
Journal:  Orphanet J Rare Dis       Date:  2013-10-10       Impact factor: 4.123

6.  Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease-associated variants, common sequence variants, and results from newborn screening.

Authors:  Douglas O S de Faria; Stijn L M In 't Groen; Marianne Hoogeveen-Westerveld; Monica Y Nino; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2020-12-21       Impact factor: 4.878

7.  From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides.

Authors:  Atze J Bergsma; Stijn Lm In 't Groen; Frans W Verheijen; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Mol Ther Nucleic Acids       Date:  2016-09-13       Impact factor: 10.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.